Bevantolol

As a representative variety of the fourth-generation β-blockers, bevantolol has both high β₁-receptor selectivity and mild α₁-receptor blocking effect. It can reduce peripheral vascular resistance while lowering blood pressure, and has less impact on lipid metabolism and glucose metabolism, so it has a better safety margin compared with traditional β-blockers. It is mainly used clinically for the treatment of essential hypertension and angina pectoris, especially suitable for elderly hypertensive patients with abnormal glucose and lipid metabolism and peripheral vascular disease. It can also be used as a basic medication for patients with coronary heart disease to improve myocardial ischemia and reduce the risk of cardiovascular events for a long time.

The prevalence of hypertension in China has remained high for a long time, with the number of patients exceeding 270 million. Coupled with the medication demand of patients with hypertension complicated with coronary heart disease, the market size of β-blocker antihypertensive drugs is stable at more than 9 billion yuan. With its differentiated clinical advantages, bevantolol has maintained a market growth rate of about 18% in recent years, which is significantly higher than the average growth rate of 4.2% for the β-blocker category. At present, there are fewer than 5 domestic generic drug declaration enterprises, and bevantolol has not been included in the national centralized volume-based procurement, so the market competition pattern is relatively loose and there is sufficient profit margin.

The original research enterprise of bevantolol is Japan Chemical Co., Ltd., and the original brand name is "Keruyun". Its core compound patent expired globally in 2011. The domestically approved original research dosage form is tablet, with specifications of 50mg and 100mg, which has been included in the *Reference Preparation Catalogue of Chemical Drugs* issued by the National Medical Products Administration. At present, 2 domestic enterprises have obtained Grade A status for their bevantolol API through CDE registration, and another 6 enterprises have obtained approval for marketing of their generic preparations, so the overall production capacity supply is stable. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for bevantolol API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products fully comply with the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the reference substance use needs of the whole process including drug development, quality research, production quality control, etc.